RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
结直肠癌免疫治疗的新兴策略：提高疗效和生存率
英文原题：Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival.
查看英文原题
Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
结直肠癌（CRC）是常见的消化系统恶性肿瘤，转移性CRC（mCRC）的总生存率持续不佳。因此，亟需开发更有效且更安全的治疗策略。近年来，免疫治疗已成为CRC治疗中的突破性方法。本综述重点介绍免疫检查点抑制剂（ICI）、癌症疫苗、溶瘤病毒疗法、过继性细胞治疗（ACT）和基质清除疗法的进展。此外，文章探讨CRC潜在的免疫治疗联合策略，强调其临床应用，并讨论CRC免疫治疗面临的挑战。通过提出克服这些局限的策略，本文旨在为不断演变的CRC免疫治疗领域提供新的见解。
展开英文摘要原文
Colorectal cancer (CRC) is a prevalent malignancy of the digestive system, with metastatic CRC (mCRC) exhibiting persistently poor overall survival rates. Consequently, there is an urgent need to develop more effective and safer therapeutic strategies. In recent years, immunotherapy has emerged as a groundbreaking approach in CRC treatment. This review highlights the advancements in immune checkpoint Inhibitors (ICIs), cancer vaccines, oncolytic virotherapy, adoptive cell therapy(ACT), and matrix-depletion therapy.
Additionally, we explore potential combinatorial immunotherapy strategies for CRC, emphasizing their clinical applications and addressing the challenges associated with CRC immunotherapy. By proposing strategies to overcome these limitations, this review aims to provide novel insights into the evolving landscape of CRC immunotherapy.
论文信息
- 作者
- Zhang Y、Guan H、Feng X、Liu M、Shao J、Liu M、He J、Jin Y
- 单位
- Yan'an Medical College, Yan'an University, Yan'an, Shaanxi, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 41112277 · DOI 10.3389/fimmu.2025.1616414
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →